Head and Neck Neoplasms  >>  Inlyta (axitinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inlyta (axitinib) / Pfizer
NCT00176748: Treatment for Patients With Metastatic Thyroid Cancer

Completed
2
3
US
AG 6013736
University of Michigan Rogel Cancer Center, Pfizer
Thyroid Cancer
08/06
06/09
NCT00094055: Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Completed
2
60
US
AG013736
Pfizer
Thyroid Neoplasms
01/09
01/09
NCT00389441: Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Completed
2
52
US, Canada, Europe, RoW
AG-013736
Pfizer
Thyroid Neoplasms
09/12
09/12
NCT01469546: Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

Completed
2
42
US
Axitinib (AG-013736)
University of Michigan Rogel Cancer Center
Head and Neck Squamous Cell Carcinoma
04/15
03/16
NCT01249547: Nasopharyngeal Carcinoma (NPC) Axitinib

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
2
37
RoW
axitinib
Chinese University of Hong Kong
Recurrent or Metastatic NPC
12/16
12/16

Download Options